- |||||||||| Retrospective data, Journal, Real-world evidence, Real-world: Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). (Pubmed Central) - Jan 30, 2024
In our study, the most prescribed drugs were secukinumab (1412), ixekizumab (1183), and risankizumab (977)...The overall probability of drug survival at four years was comparable for tildrakizumab (83.5%), ixekizumab (82.6%), guselkumab (82.4%) and brodalumab (81.8%)...Our experience showed that IL-23 inhibitors, and risankizumab in particular, had a higher probability of drug survival overall during a 4-year follow-up. Risankizumab and ixekizumab were less likely to be discontinued because of ineffectiveness after four years.
- |||||||||| Risk of Clostridioides difficile infection in patients with inflammatory bowel disease (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_2005;
For RHEUMA-Bio, the biologics included were infliximab, adalimumab, golimumab, certolizumab, ustekinumab, secukinumab, etanercept, abatacept, tocilizumab, rituximab, guselkumab and ixekizumab...Biologic therapy was not associated with a higher risk of CDI. In IBD patients on biologic therapy, the number of biologics received increased the risk of CDI.
- |||||||||| Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1637;
There was moderate certainty of evidence for combination of ADA and azathioprine (AZA) (RR 3.1, 95%CI [2.0-4.8]; risk difference [RD]: 40.1%), IFX+AZA (RR 2.5, 95%CI [1.7-3.8]; RD: 28.9%), ADA (RR 2.5, 95%CI [1.8-3.5]; RD:28.5%), and UST (RR 2.0 95%CI, [1.6-2.5]; RD: 19.2%) in induction of clinical remission compared to placebo...Conclusion On network meta-analysis, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have examples of similarly important effect sizes, but are currently limited due to the imprecision of the limited evidence base at present and future research should target these therapies in study.
- |||||||||| Tremfya (guselkumab) / J&J
Development of a Crohn's disease molecular activity score to identify region-specific chronically inflamed and non-inflamed processes (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1270; P2/3 Here, we provide a detailed molecular characterization of baseline ileal and colonic tissue from patients enrolled in the GALAXI Ph2b study of guselkumab in CD (NCT03466411) and explore the association of regional molecular profiles with endoscopic and histologic severity...Conclusion Application of the MAS to identify inflamed tissue enabled identification of key immune and inflammatory related processes across the ileum and colon that were associated with the IL-23 pathway, and baseline regional endoscopic and histologic severity. By identifying inflamed baseline samples, molecular changes associated with treatment can be more accurately defined in future analyses to better understand regional heterogeneity in CD.
- |||||||||| Tremfya (guselkumab) / J&J
Trial completion: BIOLOPTIM-GUS: Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (clinicaltrials.gov) - Jan 22, 2024 P4, N=79, Completed, By identifying inflamed baseline samples, molecular changes associated with treatment can be more accurately defined in future analyses to better understand regional heterogeneity in CD. Recruiting --> Completed
- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date, Head-to-Head: BeNeBio: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (clinicaltrials.gov) - Jan 19, 2024
P4, N=244, Active, not recruiting, No abstract available Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Dec 2025
- |||||||||| Journal: Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. (Pubmed Central) - Jan 16, 2024
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jul 2023 --> Dec 2025 No abstract available
- |||||||||| Review, Journal: The Role of IL-23 Inhibitors in Crohn's Disease. (Pubmed Central) - Jan 11, 2024
Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn's disease (CD)...Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results. In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD.
- |||||||||| Tremfya (guselkumab) / J&J
Journal: Earlier clinical response predicts low rates of radiographic progression in biologic-na (Pubmed Central) - Jan 9, 2024 In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD. In guselkumab-treated patients with active PsA, earlier improvement in joint symptoms significantly associated with lower RP rates through 2
- |||||||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Journal: Disease Characteristics, Pathogenesis, and Treatment Controversies of Axial Psoriatic Arthritis. (Pubmed Central) - Jan 9, 2024 Recent post hoc analyses of clinical trial data with IL-23 inhibitors in PsA have raised the possibility of their efficacy in axPsA and need evaluation in future clinical trials. Moreover, there is a need for classification criteria for axPsA and better tools to assess therapeutic response.
- |||||||||| Tremfya (guselkumab) / J&J
Trial completion date, Trial primary completion date: Multi-Center PAMPA Study (clinicaltrials.gov) - Jan 5, 2024 P4, N=350, Recruiting, There were no safety concerns related to the early termination of the trial. Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Dec 2025
- |||||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Enrollment closed, Combination therapy: AFFINITY: A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Jan 3, 2024 P2, N=92, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
Real-world data on the effectiveness on IBD of anti-IL23 drugs prescribed for psoriasis indication (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_945; IL-23 inhibitors demonstrated a good safety profile in patients with IBD. Despite the limitations of the study with the need to publish further real-world data on a larger scale and with higher dosing of IL-23 inhibitors, the results obtained are promising as they, for the first time, provide real-life support for the clinical potential of these drugs as treatment for IBD in addition to psoriasis.
- |||||||||| Tremfya (guselkumab) / J&J
Guselkumab binding to CD64+ IL-23 (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_682; Guselkumab (GUS) and risankizumab (RZB) are monoclonal antibodies (mAbs) specifically directed against the IL-23p19 subunit. GUS binding to CD64 on IL-23
|